Transdermal Drug Delivery Systems Market Report 2025

The transdermal drug delivery systems market size has grown strongly in recent years. It will grow from $37.3 billion in 2024 to $40.01 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to an increase in demand for non-invasive drug administration, enhanced patient compliance, improved bioavailability, growth in prevalence of chronic diseases, and a rise in preference for self-administration.

The transdermal drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $53.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing patient preference for non-invasive treatments, growing prevalence of chronic diseases, rising demand for convenient drug administration, expanding applications in pain management, and regulatory support for novel drug delivery systems. Major trends in the forecast period include advancements in personalized drug delivery, adoption of nanotechnology for enhanced absorption, the development of smart patches, improved skin penetration technologies, adoption of bioactive compounds, and innovations in wearable devices for chronic disease management.

The forecast of 7.7% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations could burden U.S. pharmaceutical manufacturers by inflating prices of microneedle array technologies and permeation enhancers imported from Japan and South Korea, resulting in delayed patch product development and higher formulation costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic diseases is expected to drive the growth of the transdermal drug delivery systems market in the future. Chronic diseases, such as diabetes and heart disease, require ongoing management and limit daily activities. Factors such as sedentary lifestyles, which lead to weight gain, poor cardiovascular health, and metabolic imbalances, contribute to the rise in chronic conditions. Transdermal drug delivery systems are used in these diseases to provide a continuous, controlled release of medication through the skin, improving patient adherence and ensuring stable therapeutic levels. For example, in June 2023, the Institute for Health Metrics and Evaluation reported that over half a billion people worldwide were living with diabetes, with this number expected to double, reaching 1.3 billion by 2050. Thus, the growing prevalence of chronic diseases is driving the market expansion for transdermal drug delivery systems.

Key players in the transdermal drug delivery systems market are concentrating on technological advancements such as microneedle technology to improve drug absorption and patient compliance. Microneedles are minimally invasive devices that deliver drugs through the skin painlessly, offering a less invasive alternative to traditional injections. For example, in October 2024, Daewoong Pharmaceutical Co. Ltd., a South Korea-based company, launched its microneedle platform CLOPAM. This platform significantly enhances drug delivery efficiency, minimizes the discomfort associated with injections, and provides controlled, sustained medication release. The goal is to offer a painless and consistent alternative to oral or injectable treatments, thereby improving patient compliance and treatment effectiveness.

In August 2022, LTS Lohmann Therapie-Systeme AG, a pharmaceutical company based in Germany, acquired Tapemark Inc. for an undisclosed amount. This acquisition strengthens LTS’s drug delivery capabilities, expanding its expertise in production and bolstering its position in the field of transdermal and advanced drug delivery solutions. Tapemark Inc., based in the US, specializes in the manufacturing of transdermal drug delivery systems.

Major players in the transdermal drug delivery systems market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, GSK plc, 3M Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan NV, UCB S.A., Skyepharma, Noven Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Watson Pharmaceuticals Inc., Endo International plc, Transdermal Technologies, Inc., Grünenthal GmbH, 4P Therapeutics LLC, and Actavis Inc.

North America was the largest region in the transdermal drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transdermal drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the transdermal drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The transdermal drug delivery systems market consists of sales of gels, creams, and microneedles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The transdermal drug delivery systems market research report is one of a series of new reports that provides transdermal drug delivery systems market statistics, including the transdermal drug delivery systems industry global market size, regional shares, competitors with the transdermal drug delivery systems market share, detailed transdermal drug delivery systems market segments, market trends, and opportunities, and any further data you may need to thrive in the transdermal drug delivery systems industry. This transdermal drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Transdermal drug delivery systems are methods used to administer medication through the skin, allowing for a controlled, continuous release of the drug into the bloodstream over a period of time. These systems are typically in the form of a patch or similar device applied to the skin, which gradually releases the medication, offering benefits such as avoiding the digestive system and ensuring stable drug levels in the body.

The main types of formulations for transdermal drug delivery systems include drug-in-patch, reservoir, matrix, and microreservoir types. The drug-in-patch formulation is especially common in the consumer health market due to its convenience, making it ideal for treatments such as nicotine replacement and hormone therapy. Key technologies used in transdermal drug delivery include iontophoresis and microporation. These systems are applied in various fields, including pain management, central nervous system disorders, cardiovascular diseases, and smoking cessation, and are used in settings such as hospitals, home healthcare, pharmaceutical companies, and research institutions.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the defined geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.